NCT05688475Active, not recruitingPhase 1
A Rollover Study of CC-122
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating CC-122
Source: ClinicalTrials.gov · Last updated 5 Nov 2026
Brief summary (registry, in English)
The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 10 Jan 2023
- Start date
- 11 Apr 2023
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Diffuse large B-cell lymphoma, Follicular lymphoma, Chronic lymphocytic leukaemia, Multiple myeloma
- NCT number
- NCT05688475
- EU CT number
- 2022-501855-97-00
- EudraCT number
- 2022-501855-97
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- From 11 Apr 2023 to the primary completion date, 30 Nov 2026
- 7 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Participants not receiving clinical benefit as assessed by the investigator. Any clinical AE, laboratory abnormality, or intercurrent illness which, in the opinion of the investigator, indicates that participation in the study is not in the best interest of the participant.
Other
- Participant is not eligible for CC-122 treatment as per the Parent Study.
- Women who are breastfeeding.
- Note: Other protocol-defined inclusion/exclusion criteria apply.
Who the study is looking for
- Participant who is currently receiving CC-122 on another CC-122 clinical trial that has met its primary and secondary endpoints.
- Participant who has participated in previous CC-122 protocol (including CC-122-ST-001 \[NCT01421524\], CC-122-ST-002 \[NCT02509039\], CC-122-DBCL-001 \[NCT02031419\], and CC-122-NHL-001 \[NCT02417285\]), and is deemed by the investigator to be deriving benefit from CC-122 as defined by the previous protocol.
- Participant who is able to tolerate study therapy and has not yet experienced progressive disease or any treatment discontinuation criteria of the Parent Study.
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Bergonie Coordinator of this site? Confirm its status | Bordeaux | France | Completed |
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Completed |
| - Coordinator of this site? Confirm its status | Koto-ku | Japan | Unknown status |
| Amsterdam UMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Completed |
| - Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| - Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.